Compare SHAZ & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SHAZ | ANL |
|---|---|---|
| Founded | 2024 | 2004 |
| Country | United States | Cayman Islands |
| Employees | N/A | N/A |
| Industry | EDP Services | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 386.9M | 406.5M |
| IPO Year | N/A | 2022 |
| Metric | SHAZ | ANL |
|---|---|---|
| Price | $26.57 | $11.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | 124.0K | ★ 229.5K |
| Earning Date | 06-23-2026 | 04-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.55 | $0.88 |
| 52 Week High | $31.95 | $12.09 |
| Indicator | SHAZ | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 51.43 | 74.42 |
| Support Level | $16.75 | $1.36 |
| Resistance Level | $27.95 | $12.09 |
| Average True Range (ATR) | 2.53 | 0.97 |
| MACD | 0.59 | 0.38 |
| Stochastic Oscillator | 71.88 | 98.73 |
SharonAI Holdings Inc is a high-performance computing (HPC) company deploying large-scale energy and compute infrastructure, USA energy markets and infrastructure asset management. Its services include: Sovereign AI Australia, GPU-as-a-Service, SHARON AI Cloud, SHARON AI Private Cloud, Virtual Private Clusters, HPC Servers, SHARON AI Supercluster, GPU Fleet, Virtual Servers, Cloud Storage, AI Model Training, High-Performance Computing (HPC), and Video Encoding & Decoding. The company's products are: Sovereign AI Australia, GPU-as-a-Service, SHARON AI Cloud, SHARON AI Private Cloud, Virtual Private Clusters, HPC Servers, SHARON AI Supercluster, GPU Fleet, Virtual Servers, Cloud Storage, AI Model Training, High Performance Computing (HPC), and Video Encoding & Decoding.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.